Market Research Life Sciences Market Research Pharmaceuticals Market Research Clinical Trial Market Research

Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029

Best Price Guarantee Length Publisher Published Date SKU
from $10,995 139 Pages GlobalData July, 2023 GBDT18095353
Best Price Guarantee
Price from $10,995
Length 139 Pages
Publisher GlobalData
Published Date July, 2023
SKU GBDT18095353

Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029


Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Parkinson's Disease market through 2029.

Parkinson’s disease (PD) is a chronic and progressive disease. The primary pathological features of PD are loss of dopaminergic neurons of the substantia nigra and protein accumulations known as Lewy bodies. It is important to note that while degeneration of the dopaminergic neurons is the most characteristic and well-studied feature of the disease, pathological changes are seen in other parts of the brain and may account for non-motor symptoms.

Growth in the PD market is expected to be driven by a growing aging population coupled with the launch of 14 pipeline products across the 7MM.

Key Highlights

Forecasts includes the 7MM
Forecasts covers from 2019-2029

Scope
  • Overview of PD, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized PD treatment market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PD therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
  • Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Please note: this is delivered as an Excel file.


1 Parkinson’s Disease: Executive Summary – Updated June 2023, Based on Events Up to June 30, 2023
1.1 Parkinson’s market expected to grow significantly, driven by new launches
1.2 Significant opportunities and risks for disease-modifying therapies entering the PD market
1.3 Diverse pipeline agents will partially address key unmet needs
1.4 The advancement of levodopa delivery systems will shape the PD market
1.5 What do physicians think?
2 Introduction – Updated June 2023
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview – Updated June 2023
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Mechanisms of cell death
3.2 Classification or staging systems
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.5 Epidemiological forecast for PD (2019–29)
4.5.1 Diagnosed prevalent cases of PD
4.5.2 Sex-specific diagnosed prevalent cases of PD
4.5.3 Age-specific diagnosed prevalent cases of PD
4.5.4 Diagnosed prevalent cases of PD by Hoehn and Yahr clinical staging
4.5.5 Diagnosed prevalent cases of PD by type
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management – Updated June 2023, Based on Events Up to June 30, 2023
5.1 Diagnosis and treatment overview
5.2 Key opinion leader insights on disease management
6 Competitive Assessment – Updated June 2023, Based on Events Up to June 30, 2023
6.1 Overview
7 Unmet Needs and Opportunity Assessment – Updated June 2023, Based on Events Up to June 30, 2023
7.1 Overview
7.2 Effective treatment of motor complications – dyskinesia, off episodes, gait, and balance problems
7.3 New therapies for non-motor complications – psychosis and dementia
7.4 Neuroprotective or disease-modifying agents
7.5 Improved drug formulations
8 R&D Strategies – Updated June 2023, Based on Events Up to June 30, 2023
8.1 Overview
8.1.1 Development of novel targets ─ mAbs targeting α-synuclein and gene therapies
8.1.2 Innovative drug delivery systems
8.1.3 Secondary indications and drug repurposing
8.1.4 Clinical trial design
8.1.5 Reliable biomarkers of disease progression
8.1.6 Genetic studies required to learn about genetic subtypes of PD
9 Pipeline Assessment – Updated June 2023, Based on Events Up to June 30, 2023
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis – Updated June 2023, Based on Events Up to June 30, 2023
10.1 Overview
10.2 Competitive assessment
10.2.1 Levodopa therapy
10.2.2 Dopamine agonists
10.2.3 Products targeting non-motor symptoms
10.2.4 Non-levodopa therapies
10.2.5 Therapies for levodopa-induced dyskinesia
11 Current and Future Players – Updated June 2023, Based on Events Up to June 30, 2023
11.1 Overview
11.2 Deal-making trends
12 Market Outlook – Updated June 2023, Based on Events Up to June 30, 2023
12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers – global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research – key opinion leaders interviewed for this report
13.4.1 Key opinion leaders
13.5 Primary research – prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologist
13.6.5 Vice President of Disease Analysis and Intelligence
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
Contact Us
List of Tables
Table 1: PD: key metrics in the 7MM
Table 2: Modified HY scale of PD symptoms
Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2019
Table 4: Risk factors and comorbidities of PD
Table 5: Treatment guidelines for PD
Table 6: PD market – global drivers and barriers, 2019–29
Table 7: Key events impacting sales for PD in the US, 2019–29
Table 8: PD market – drivers and barriers in the US, 2019–29
Table 9: Key events impacting sales for PD in the 5EU, 2019–29
Table 10: PD market – drivers and barriers in the 5EU, 2019–29
Table 11: Key events impacting sales for PD in Japan, 2019–29
Table 12: PD market – drivers and barriers in Japan, 2019–29
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for PD in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in PD During the Forecast Period
Figure 3: 7MM, diagnosed prevalence (%) of PD, both sexes, ages ≥18 years, 2019
Figure 4: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PD
Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by HY clinical staging
Figure 6: 7MM, diagnosed prevalent cases of PD, both sexes, N, ages ≥18 years, 2019
Figure 7: 7MM, diagnosed prevalent cases of PD by sex, N, ages ≥18 years, 2019
Figure 8: 7MM, diagnosed prevalent cases of PD by age, N, both sexes, 2019
Figure 9: 7MM, diagnosed prevalent cases of PD by HY clinical staging, N, both sexes, ages ≥18 years, 2019
Figure 10: 7MM, diagnosed prevalent cases of PD by type, N, both sexes, ages ≥18 years, 2019
Figure 11: Treatment algorithm for PD patients
Figure 12: Unmet needs and opportunities in PD
Figure 13: Pharmacokinetics of levodopa
Figure 14: Overview of the development pipeline in PD
Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PD in the 7MM during the forecast period
Figure 16: Competitive assessment of the pipeline levodopa therapies benchmarked against the SOC, Sinemet
Figure 17: Competitive assessment of the pipeline dopamine agonist drugs benchmarked against the SOC, Requip XL
Figure 18: Competitive assessment of blarcamesine benchmarked against the SOC, Nuplazid
Figure 19: Competitive assessment of the pipeline non-levodopa drugs benchmarked against the SOC, Azilect
Figure 20: Competitive assessment of the pipeline levodopa-induced dyskinesia drugs benchmarked against the SOC, Gocovri (amantadine ER)
Figure 21: Analysis of the company portfolio gap in PD during the forecast period (2019–29)
Figure 22: Global (7MM) sales forecast by country for PD in 2019 and 2029
Figure 23: Sales forecast by class for PD in the US in 2019 and 2029
Figure 24: Sales forecast by class for PD in the 5EU in 2019 and 2029
Figure 25: Sales forecast by class for PD in Japan in 2019 and 2029

$10,995
$21,990
$32,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings